Asustek Computer, a leading innovator in personal computing products, will bundle three-dimensional motion controllers from Leap Motion with select new computers. In an industry first, Asus will bundle the 3D motion-control technology into new high-end notebooks and premium all-in-one (AiO) PCs powered by Intel Corp.’s code-named Haswell processors later this year.
“Our commitment to innovation and exceptional quality drive us to provide the best technology to our consumers. Leap Motion has developed an exciting technology that will truly enhance the experience our customers have with their Asus devices, opening a world of opportunity for personal use and business, from entertainment to architecture to education. We are proud to be one of the first companies to partner with Leap Motion,” said Albert Wu, desktop division senior director at Asustek.
Leap Motion’s technology – which relies on a special receiver hardware and custom software – can track movements to 1/100th millimeter with no visible lag time. The Leap Motion controller has a 150-degree field of view, and tracks individual hands and all 10 fingers at 290 frames per second. The partnership between Asus and Leap Motion brings the future of computer interaction – Leap Motion’s incredibly fast and accurate natural user interface – to millions of potential consumers around the world.
“As OEMs adopt 3D motion control technology, they’re spurring a rapid evolution in computer interface innovations and helping free the full power and potential of computingfor consumers. This historic partnership with Asus is an important step in building global adoption of the new computing paradigm Leap Motion’s technology offers. We’re delighted that Asus shares our outlook on the future of human/computer interaction,” said Michael Buckwald, Leap Motion co-founder and CEO.
A standalone Leap Motion device will ship to consumers early this year, and can be pre-ordered for $70 at the company’s web-site.
Archive for January 4th, 2013
Posted by Xeno on January 4, 2013
Posted by Xeno on January 4, 2013
The first genetically engineered salmon – dubbed “frankenfish” – could be in grocery stores and restaurants as early as 2014. The FDA is expected to approve AquaBounty Technologies’ GE salmon after a 60-day public comment period. If approved, it will be the first approved food from a transgenic animal application to enter the U.S. food supply.
Consumer and environmental activists oppose genetically engineered “frankenfish” for many reasons, including the potential danger it poses to human health, to the environment and to the U.S. fishing economy. Michael Hansen, PhD, senior scientist with the Consumers Union, the advocacy and policy arm of Consumer Reports, called the FDA’s Environmental Assessment (EA) of GE salmon “flawed and inadequate.”
Please sign the petition (at the bottom of the page) if you agree that the FDA should reject should AquaBounty’s genetically engineered salmon, at least until it completes further, more reliable safety testing.
What is frankenfish?
AquaBounty Technologies, a Massachusetts-based biotech company, created the “AquAdvantage” salmon by injecting a fragment of DNA from an ocean pout fish, which is a type of eel, along with a growth hormone gene from the Chinook Pacific salmon, into a fertilised Atlantic salmon egg. The result? A salmon that produces growth hormone year round, instead of only during warm weather. This allows the fish to reach market weight in just 18 months, instead of the usual three years.
Potential harm to human health. The FDA has allowed this fish to move forward based on tests of allergenicity of only six GE fish. Even with such limited testing, the results showed an increase in allergy-causing potential, according to Hansen. AquAdvantage also contains elevated levels of the growth hormone, IGF-1, which is linked to prostate, breast and colon cancers….
If this is not stopped, the very good reason that salmon don’t get this big this fast in nature will only be discovered after we have destroyed another natural resource and further damaged our health.